What is Puma Biotechnology?
Headquartered in Los Angeles, California, Puma Biotechnology, Inc. operates as a specialized biopharmaceutical entity dedicated to the research and development of innovative drug candidates. The company maintains a sharp focus on oncology, targeting various forms of cancer through advanced clinical-testing protocols. By positioning itself at the intersection of biotechnology and precision medicine, Puma Biotechnology aims to transform the standard of care for patients facing aggressive malignancies. Its market position is defined by its commitment to rigorous scientific validation and the strategic pursuit of therapeutic breakthroughs that hold significant commercial and clinical value.
How much funding has Puma Biotechnology raised?
Puma Biotechnology has raised a total of $840.4M across 7 funding rounds:
Share Placement
$55M
Share Placement
$60M
Stock Offering
$129.1M
Stock Offering
$129.3M
Stock Offering
$205M
Stock Offering
$162M
Debt
$100M
Share Placement (2011): $55M with participation from Orbimed Private Investments, Jennison Associates, T. Rowe Price Associates, Adage Capital Management, Tekla Healthcare Opportunities, Brookside Capital, and H&Q Life Science Investors
Share Placement (2011): $60M led by Orbimed Private Investments, Jennison Associates, T. Rowe Price Associates, Adage Capital Management, Tekla Healthcare Opportunities, Brookside Capital, and H&Q Life Science Investors
Stock Issuance/Offering (2012): $129.1M supported by Undisclosed
Stock Issuance/Offering (2014): $129.3M featuring Undisclosed
Stock Issuance/Offering (2015): $205M backed by Undisclosed
Stock Issuance/Offering (2016): $162M with participation from Undisclosed
Debt (2017): $100M led by Silicon Valley Bank and Oxford Finance
Key Investors in Puma Biotechnology
T. Rowe Price Associates
A global asset management organization providing investment solutions across equities and fixed income, known for its active management and fundamental research approach.
Jennison Associates
An investment firm established in 1969 that offers a diverse range of equity and fixed income services to institutional and individual clients.
Brookside Capital
A division of Bain Capital, this firm specializes in private equity and growth capital, partnering with visionary leaders to accelerate business transformation.
What's next for Puma Biotechnology?
Looking ahead, the strategic deployment of the $100M will likely be directed toward accelerating the clinical development of its core drug portfolio. As the company matures, the focus will shift from initial capital accumulation to achieving key regulatory approvals and establishing commercial infrastructure. The ongoing support from institutional investors suggests a robust outlook for the company's ability to navigate the high-stakes environment of drug development. Future growth will depend on the successful translation of clinical data into therapeutic efficacy, ensuring that Puma Biotechnology remains a competitive force in the global biopharmaceutical sector.
See full Puma Biotechnology company page
